Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEIA: Osimertinib vs Durvalumab After Concurrent Chemoradiotherapy in Unresectable EGFR-mutated LA-NSCLC
jRCT1031250864Phase 3Recruiting
- Sponsor
- Japan Clinical Oncology Group
- Start
- Apr 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Osimertinib maintenance therapy with Durvalumab consolidation therapy (2 arms). Primary endpoint: Overall survival. Started Apr 2026; status: recruiting.
02
Drugs
osimertinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031250864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250864.